SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix Pharmaceuticals announced the first patient dosed in its Phase 3…

Telix Pharmaceuticals Limited · PRESS-RELEASE filed Jul 20, 2026 at 17:00 ET

At the news

BULLISHIMPACT 4/10

PRESS-RELEASE filed Jul 20, 2026 at 17:00 ET

Telix Pharmaceuticals announced the first patient dosed in its Phase 3 LUTEON1 trial evaluating TLX250-Tx, a CAIX-targeted radiopharmaceutical therapy, in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). This is a positive clinical milestone, but the event is procedural without financial data or near-term catalysts, and the company's stock has historically not reacted strongly to similar announcements.

  • First patient dosed in the Phase 3 LUTEON1 trial of TLX250-Tx for relapsed or recurrent ccRCC.
  • LUTEON1 is the first Phase 3 study of a CAIX-targeted radiopharmaceutical therapy in ccRCC.
  • Telix has a commercial imaging franchise (Illuccix, Gozellix) and multiple late-stage therapeutic candidates, including TLX250-Tx.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access